Type 2 Diabetes

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

New research suggests signs a person may be more susceptible to type 2 diabetes later in life are visible in children as young as 8 years old.

The FDA's approval of insulin lispro-aabc injection is based on the results of 2 phase 3 trials—PRONTO-T1D and PRONTO-T2D.

Both type 1 and type 2 diabetics now have an additional insulin option available to them in the form of insulin lispro-aabc injection (Lyumjev) 100 units/mL and 200 units/mL.

A pooled analysis of 5 PIONEER trials presented by John Buse, MD, at ADA 2020 is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

Women with recent gestational diabetes who use the intervention see less retention of weight than those who do not use the intervention.

An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

The drug also reduced the risk of myocardial infarction and stroke.

Taking testosterone while enrolled in a lifestyle program reduces glucose levels and risk of type 2 diabetes.

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Results of the VERTIS-CV trial indicate ertugliflozin could reduce heart failure hospitalizations but did not demonstrate the ability to reduce MACE compared to placebo.

Todd Hobbs, MD, breaks down research presented at ADA 2020.

Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

The prevention of type 2 diabetes is possible and has important clinical benefits.

Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.

An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.

New data released today from the Diabetes Prevention Program Outcomes Study (DPPOS) shows that in over 2000 patients followed for an average of 22 years, lifestyle programs and treatment with metformin continues to prevent the development of type 2 diabetes in at risk populations.

New data released today from the Diabetes Prevention Program Outcomes Study (DPPOS) shows that in over 2000 patients followed for an average of 22 years, lifestyle programs and treatment with metformin continues to prevent the development of type 2 diabetes (T2D) in at risk populations.

Data from a phase 2 trial presented at ADA 2020 suggests ladarixin, a CXCR1/2 inhibitor, could provide benefit to patients with type 1 diabetes.

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

An investigator provides an update on the TEDDY study.

Sirimon Reutrakul, MD, discusses what providers should do based on the findings of a new study presented at ADA 2020.

A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.